Annual Report

Overview

The report describes Regeneron's rapid development and authorization of REGEN-COV for COVID-19, alongside FDA approvals for Inmazeb and Evkeeza. It reports 30 investigational medicines in clinical development, 9,100 total employees, and 2020 total revenues of $8.5 billion. The Responsible Regeneron section organizes its efforts around improving patients' lives, fostering integrity and excellence, and building sustainable communities. It also notes climate-related reporting aligned with TCFD and continued alignment of the 2020 Responsibility Report with SASB.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2020
Period: Ends 31 December 2020
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services